Norimitsu Inoue

Prof. Norimitsu Inoue


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TOToshimitsu Ohashi
Toshimitsu Ohashi
TATakashi Akazawa
Takashi Akazawa
MAMitsuhiro Aoki
Mitsuhiro Aoki
BKBunya Kuze
Bunya Kuze
KMKeisuke Mizuta
Keisuke Mizuta
NINorimitsu Inoue
Norimitsu Inoue
The activation of oncogenic signaling pathways induces the reprogramming of glucose metabolism in tumor cells and increases lactic acid secretion into the tumor microenvironment. This is a well‐known characteristic of tumor cells, termed the Warburg effect, and is a candidate target for antitumor therapy. Previous reports show that lactic acid secreted by tumor cells is a proinflammatory mediator that activates the IL‐23/IL‐17 pathway, thereby inducing inflammation, angiogenesis and tissue remodeling. Here, we show that lactic acid, or more specifically the acidification it causes, increases arginase I (ARG1) expression in macrophages to inhibit T‐cell proliferation and activation. Accordingly, we hypothesized that counteraction of the immune effects by lactic acid might suppress tumor development. We show that dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinases, targets macrophages to suppress activation of the IL‐23/IL‐17 pathway and the expression of ARG1 by lactic acid. Furthermore, lactic acid‐pretreated macrophages inhibited CD8+ T‐cell proliferation, but CD8+ T‐cell proliferation was restored when macrophages were pretreated with lactic acid and DCA. DCA treatment decreased ARG1 expression in tumor‐infiltrating immune cells and increased the number of IFN‐γ‐producing CD8+ T cells and NK cells in tumor‐bearing mouse spleen. Although DCA treatment alone did not suppress tumor growth, it increased antitumor immunotherapeutic activity of Poly(IC) in both CD8+ T cell‐ and NK cell‐sensitive tumor models. Therefore, DCA acts not only on tumor cells to suppress glycolysis but also on immune cells to improve the immune status modulated by lactic acid and to increase the effectiveness of antitumor immunotherapy.

19 May 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
TOToshimitsu Ohashi
Toshimitsu Ohashi
MAMitsuhiro Aoki
Mitsuhiro Aoki
HTHiroyuki Tomita
Hiroyuki Tomita
TATakashi Akazawa
Takashi Akazawa
KSKatsuya Sato
Katsuya Sato
YIYatsuji Ito
Yatsuji Ito
Reprogramming of glucose metabolism in tumor cells is referred to as the Warburg effect and results in increased lactic acid secretion into the tumor microenvironment. We have previously shown that lactic acid has important roles as a pro‐inflammatory and immunosuppressive mediator and promotes tumor progression. In this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC). Tumors expressing lower levels of LDHA and GLUT1 had a higher concentration of lactic acid than those with higher LDHA and GLUT1 expression. Lactic acid also suppressed the expression of LDHA and GLUT1 in vitro. We previously reported that lactic acid enhances expression of an M2 macrophage marker, ARG1, in murine macrophages. Therefore, we investigated the relationship between the lactic acid concentration and polarization of M2 macrophages in HNSCC by measuring the expression of M2 macrophage markers, CSF1R and CD163, normalized using a pan‐macrophage marker, CD68. Tumors with lower levels of CD68 showed a higher concentration of lactic acid, whereas those with higher levels of CSF1R showed a significantly higher concentration of lactic acid. A similar tendency was observed for CD163. These results suggest that tumor‐secreted lactic acid is linked to the reduction of macrophages in tumors and promotes induction of M2‐like macrophage polarization in human HNSCC.

1 May 2007 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
KTKeiko Takahashi
Keiko Takahashi
NYNaofumi Yoshida
Naofumi Yoshida
NMNaoko Murakami
Naoko Murakami
KKKiyo Kawata
Kiyo Kawata
HIHiroyuki Ishizaki
Hiroyuki Ishizaki
NINorimitsu Inoue
Norimitsu Inoue
The tumor suppressor p53 is a key transcriptional factor regulating the induction of cellular senescence by oncogenic signals. The activity of p53 is regulated by recruitment into promyelocytic leukemia (PML)-nuclear bodies (NBs) as well as by stabilization through posttranslational modifications such as phosphorylation and acetylation. Here we found that MORC3 (microrchidia3)-ATPase activated p53 and induced cellular senescence in normal human and mouse fibroblasts but not p53−/− fibroblasts. Conversely, genotoxic stress–induced phosphorylation and stabilization of p53 but barely increased its transcriptional activity in Morc3−/− fibroblasts. MORC3 localized on PML-NBs in presence of PML and mediated recruitment of p53 and CREB-binding protein (CBP) into PML-NBs. In contrast, expression of ATPase activity-deficient mutant MORC3-E35A or siRNA repression of MORC3 impaired the localization of p53 and Sp100 but not CBP on PML-NBs. These results suggest that MORC3 regulates p53 activity and localization into PML-NBs. We identified a new molecular mechanism that regulates the activity of nuclear proteins by localization to a nuclear subdomain.

15 June 2010 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
YMYasuhiro Mimura
Yasuhiro Mimura
KTKeiko Takahashi
Keiko Takahashi
KKKiyo Kawata
Kiyo Kawata
TATakashi Akazawa
Takashi Akazawa
NINorimitsu Inoue
Norimitsu Inoue
Many functional subdomains, including promyelocytic leukemia nuclear bodies (PML NBs), are formed in the mammalian nucleus. Various proteins are constitutively or transiently accumulated in PML NBs in a PML-dependent manner. MORC3 (microrchidia family CW-type zinc-finger 3), also known as NXP2, which consists of GHL-ATPase, a CW-type zinc-finger and coiled-coil domains, is localized in PML NBs, where it recruits and activates p53 to induce cellular senescence. Interestingly, we found that MORC3 can form PML-independent nuclear domains (NDs) in mouse hematopoietic cells and even in Pml-deficient cells. Here, we show that MORC3 colocalizes with PML by a two-step molecular mechanism: the PML-independent formation of MORC3 NDs by the ATPase cycle, and the association of MORC3 with PML via the SUMO1-SUMO-interacting motif (SIM). Similarly to other members of the GHL-ATPase family, MORC3 functions as a ‘molecular clamp’. ATP binding induces conformational changes in MORC3, leading to the formation of MORC3 NDs, and subsequent ATP hydrolysis mediates the diffusion and binding of MORC3 to the nuclear matrix. MORC3 might clamp DNA or nucleosomes in MORC3 NDs via the CW domain. Furthermore, the SUMOylation of MORC3 at five sites was involved in the association of MORC3 with PML, and SUMO1-unmodified MORC3 formed NDs independently of PML.

13 July 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
HOHiroshi Okamura
Hiroshi Okamura
HNHirohisa Nakamae
Hirohisa Nakamae
TSTakero Shindo
Takero Shindo
KOKatsuki Ohtani
Katsuki Ohtani
YHYoshihiko Hidaka
Yoshihiko Hidaka
NINorimitsu Inoue
Norimitsu Inoue
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous reports suggest that TA-TMA is caused by complement activation by complement-related genetic variants; however, this needs to be verified, especially in adults. Here, we performed a nested case-control study of allo-HSCT-treated adults at a single center. Fifteen TA-TMA patients and 15 non-TA-TMA patients, matched according to the propensity score, were enrolled. Based on a previous report showing an association between complement-related genes and development of TA-TMA, we first sequenced these 17 genes. Both cohorts harbored several genetic variants with rare allele frequencies; however, there was no difference in the percentage of patients in the TA-TMA and non-TA-TMA groups with the rare variants, or in the average number of rare variants per patient. Second, we measured plasma concentrations of complement proteins. Notably, levels of Ba protein on Day 7 following allo-HSCT were abnormally and significantly higher in TA-TMA than in non-TA-TMA cases, suggesting that complement activation via the alternative pathway contributes to TA-TMA. All other parameters, including soluble C5b-9, on Day 7 were similar between the groups. The levels of C3, C4, CH50, and complement factors H and I in the TA-TMA group after Day 28 were significantly lower than those in the non-TA-TMA group. Complement-related genetic variants did not predict TA-TMA development. By contrast, abnormally high levels of Ba on Day 7 did predict development of TA-TMA and non-relapse mortality. Thus, Ba levels on Day 7 after allo-HSCT are a sensitive and prognostic biomarker of TA-TMA.

31 October 2024 in International Journal of Cancer
Verified
Journal Article
Closed access
SMSatoshi Muraoka
Satoshi Muraoka
TBTakashi Baba
Takashi Baba
TATakashi Akazawa
Takashi Akazawa
KKKei‐Ichi Katayama
Kei‐Ichi Katayama
HKHiroki Kusumoto
Hiroki Kusumoto
NINorimitsu Inoue
Norimitsu Inoue